Table 5.
Resistance Rates of MRSA and MSSA to the Common Antibiotics
| MRSA | MSSA | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1998–2002 | 2003–2007 | 2008–2012 | 2013–2017 | 1998–2002 | 2003–2007 | 2008–2012 | 2013–2017 | |||||||||
| n | R (%) | n | R (%) | n | R (%) | n | R (%) | n | R (%) | n | R (%) | n | R (%) | n | R (%) | |
| Aminoglycosides | ||||||||||||||||
| Gentamicin (10ug) | 89 | 38.2 | 345 | 55.4 | 442 | 56.6 | 520 | 77.9 | 305 | 5.6 | 431 | 9.7 | 524 | 10.5 | 421 | 10.7 |
| Fluoroquinolones | ||||||||||||||||
| Levofloxacin (5ug) | / | / | / | / | 380 | 53.9 | 455 | 82.6 | / | / | / | / | 446 | 7.8 | 305 | 7.5 |
| Folate pathway antagonists | ||||||||||||||||
| Trimethoprim/sulfamethoxazole (1.25/23.75ug) | 83 | 69.9 | 379 | 64.9 | 435 | 41.1 | 504 | 3.8 | 300 | 26.7 | 449 | 29.2 | 501 | 22.2 | 397 | 3.3 |
| Lincosamides | ||||||||||||||||
| Clindamycin (2ug) | 72 | 61.1 | 388 | 67.5 | 462 | 63.6 | 514 | 55.3 | 265 | 30.6 | 446 | 28.7 | 541 | 21.4 | 401 | 19.5 |
| Macrolides | ||||||||||||||||
| Erythromycin (15ug) | 90 | 85.6 | 393 | 89.1 | 461 | 85.7 | 526 | 72.4 | 313 | 62.3 | 451 | 54.8 | 540 | 54.1 | 422 | 46.2 |
| Oxazolidinones | ||||||||||||||||
| Linezolid (30ug) | / | / | / | / | / | / | 487 | 0 | / | / | / | / | / | / | 376 | 0 |
| Glycopeptides | ||||||||||||||||
| Vancomycin (30ug) | 90 | 0 | 393 | 0 | 370 | 0 | 475 | 0 | 319 | 0 | 454 | 0 | 444 | 0 | 326 | 0 |
| Teicoplanin (30ug) | / | / | 360 | 1.1 | 434 | 1.2 | 491 | 0.2 | / | / | 424 | 0 | 476 | 0.2 | 329 | 0 |
Note: “/” indicated that the antibiotics had not been tested.